[go: up one dir, main page]

AR097111A1 - COMBINATION AND METHOD FOR THE ADMINISTRATION OF AN ANIMAL - Google Patents

COMBINATION AND METHOD FOR THE ADMINISTRATION OF AN ANIMAL

Info

Publication number
AR097111A1
AR097111A1 ARP140102826A ARP140102826A AR097111A1 AR 097111 A1 AR097111 A1 AR 097111A1 AR P140102826 A ARP140102826 A AR P140102826A AR P140102826 A ARP140102826 A AR P140102826A AR 097111 A1 AR097111 A1 AR 097111A1
Authority
AR
Argentina
Prior art keywords
combination
animal
administration
material containing
plant material
Prior art date
Application number
ARP140102826A
Other languages
Spanish (es)
Original Assignee
Omnigen Res L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnigen Res L L C filed Critical Omnigen Res L L C
Publication of AR097111A1 publication Critical patent/AR097111A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se revelan las formas de realización de una combinación y método para la administración a un animal. El animal puede tener -o estar en riesgo de contraer- un trastorno inflamatorio. La combinación incluye: (a) material vegetal que contiene polifenoles, un extracto vegetal derivado del material vegetal que contiene polifenoles o una mezcla de ellos; y (b) glucano, sílice, arcilla mineral, mananos o cualquier combinación de ellos.The embodiments of a combination and method for administration to an animal are disclosed. The animal may have - or be at risk for - an inflammatory disorder. The combination includes: (a) plant material containing polyphenols, a plant extract derived from plant material containing polyphenols or a mixture thereof; and (b) glucan, silica, mineral clay, mannan or any combination thereof.

ARP140102826A 2013-07-29 2014-07-29 COMBINATION AND METHOD FOR THE ADMINISTRATION OF AN ANIMAL AR097111A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361859689P 2013-07-29 2013-07-29

Publications (1)

Publication Number Publication Date
AR097111A1 true AR097111A1 (en) 2016-02-17

Family

ID=51355650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102826A AR097111A1 (en) 2013-07-29 2014-07-29 COMBINATION AND METHOD FOR THE ADMINISTRATION OF AN ANIMAL

Country Status (3)

Country Link
AR (1) AR097111A1 (en)
TW (1) TW201601730A (en)
WO (1) WO2015017336A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219603B (en) * 2016-06-01 2025-06-27 礼蓝动物保健有限公司 Substituted indazoles for the treatment and prevention of allergic and/or inflammatory diseases in animals
AU2018212566B2 (en) * 2017-01-24 2022-11-24 OmniGen Research, L.L.C. Granulated feed supplement and methods for making and using
CN114177187B (en) * 2021-12-10 2024-10-22 西北大学 Application of sheep milk acidic free oligosaccharides rich in α2,6-sialic acid modification in the preparation of immunomodulatory drugs or functional foods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143146B4 (en) * 2001-09-03 2009-06-10 Boers, Johannes, Dr. med. vet. Anti-arthritic preparation and its use
US20080317885A1 (en) * 2005-07-15 2008-12-25 Baker Donald J Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
WO2010097643A1 (en) * 2009-02-24 2010-09-02 Novatech Istrazivanje D.O.O. Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
HUE052368T2 (en) * 2012-10-02 2021-04-28 Oil Dri Corp Of America Clay product and uses thereof

Also Published As

Publication number Publication date
WO2015017336A1 (en) 2015-02-05
TW201601730A (en) 2016-01-16

Similar Documents

Publication Publication Date Title
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CL2016000153A1 (en) Glioxamide substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis b
CL2016000017A1 (en) 4-member ring carboxamides used as nematicides
UY35500A (en) INDAZOLS REPLACED WITH HETEROARILO
MX386298B (en) PHARMACEUTICAL COMPOSITION INCLUDING ADALIMUMAB.
CL2017000394A1 (en) Composition containing cineole for nasal administration
CL2016000009A1 (en) Papulopustular rosacea treatment with ivermectin.
CL2015001772A1 (en) Pharmaceutical composition for the treatment of headache, and method of preparing it.
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
CL2015003713A1 (en) Herbicidal composition that has improved plant safety
CR20170005A (en) INSOINDOLINE DERIVATIVES
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
CL2016001210A1 (en) Analogs of bicalutamide or (s) - bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal accumulation disorder or glycogenosis.
SV2017005466A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
CL2016000038A1 (en) Pyroxolo-substituted pyridinamines
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
DOP2015000298A (en) NEW COMPOUNDS FOR CANCER TREATMENT
CL2014001862A1 (en) Compounds derived from substituted moropholinyl, useful as mogat-2 inhibitors; pharmaceutical composition that includes them; use in the treatment of hypertriglyceridemia.
UY36217A (en) PIRIDONA SUBSTITUTE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
CL2015003433A1 (en) Tylosin derivatives and method for their preparation
AR097111A1 (en) COMBINATION AND METHOD FOR THE ADMINISTRATION OF AN ANIMAL
CL2015003460A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for the treatment of an ophthalmic disease
CL2015001502A1 (en) Pharmaceutical composition comprising desloratadine and prendnisolone and use thereof.
CU20170134A7 (en) 2-THIOPIRIMIDINONES
CL2016002653A1 (en) Pharmaceutical combination comprising brexpiprazole and nalmefene; pharmaceutical composition comprising them; pharmaceutical kit; and use of the combination for the prevention and treatment of a disorder related to substances such as alcohol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure